Medifast, Inc. (MED) Analysts See $0.48 EPS

February 24, 2018 - By Michael Collier

 Medifast, Inc. (MED) Analysts See $0.48 EPS
Investors sentiment decreased to 1 in 2017 Q3. Its down 0.11, from 1.11 in 2017Q2. It turned negative, as 15 investors sold Medifast, Inc. shares while 60 reduced holdings. 31 funds opened positions while 44 raised stakes. 10.20 million shares or 2.70% less from 10.48 million shares in 2017Q2 were reported.
Schwab Charles Mgmt holds 0% or 45,252 shares in its portfolio. Hightower Advsrs Llc holds 0% or 5,335 shares. New York State Common Retirement Fund accumulated 11,700 shares or 0% of the stock. Wells Fargo & Company Mn accumulated 0% or 60,327 shares. Mutual Of America Ltd Liability Corp, a New York-based fund reported 1,735 shares. Rhumbline Advisers reported 21,831 shares stake. Smith Asset Gru Lp invested in 0% or 1,818 shares. Mason Street Advsrs Ltd Liability Co has 2,659 shares for 0% of their portfolio. First Advisors Ltd Partnership has 0% invested in Medifast, Inc. (NYSE:MED) for 8,293 shares. Chickasaw Cap Limited Company holds 0.07% or 55,148 shares. Martingale Asset Mngmt Limited Partnership accumulated 0.05% or 60,306 shares. Kennedy Capital Management Inc holds 0.29% of its portfolio in Medifast, Inc. (NYSE:MED) for 275,404 shares. California-based Eam Invsts Limited has invested 0.37% in Medifast, Inc. (NYSE:MED). Amp Cap Investors has invested 0% in Medifast, Inc. (NYSE:MED). Chicago Equity Prns Limited reported 5,955 shares.

Analysts expect Medifast, Inc. (NYSE:MED) to report $0.48 EPS on March, 8.They anticipate $0.14 EPS change or 41.18 % from last quarter’s $0.34 EPS. MED’s profit would be $5.73M giving it 34.63 P/E if the $0.48 EPS is correct. After having $0.55 EPS previously, Medifast, Inc.’s analysts see -12.73 % EPS growth. The stock increased 0.83% or $0.55 during the last trading session, reaching $66.48. About 42,738 shares traded. Medifast, Inc. (NYSE:MED) has risen 25.81% since February 24, 2017 and is uptrending. It has outperformed by 9.11% the S&P500.

Medifast, Inc. (NYSE:MED) Ratings Coverage

Among 3 analysts covering Medifast (NYSE:MED), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Medifast had 7 analyst reports since August 10, 2015 according to SRatingsIntel. The rating was downgraded by Sidoti on Monday, November 30 to “Neutral”. The stock has “Buy” rating by Sidoti on Monday, October 5. As per Monday, August 10, the company rating was downgraded by Zacks. On Monday, January 11 the stock rating was upgraded by Sidoti to “Buy”. The stock of Medifast, Inc. (NYSE:MED) has “Hold” rating given on Friday, January 29 by Wunderlich. DA Davidson initiated the shares of MED in report on Wednesday, August 16 with “Buy” rating. DA Davidson maintained the stock with “Buy” rating in Friday, September 15 report.

Medifast, Inc., through its subsidiaries, produces, distributes, and sells weight loss, weight management, healthy living products, and other consumable health and diet products. The company has market cap of $793.35 million. The firm offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, eggs, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape For Life, Flavors of Home, and Essential 1 brands, as well as Dual Fuel, a sports nutrition pilot program. It has a 32.73 P/E ratio. It also provides meal replacements comprising vitamins and minerals; and hydration products, as well as other nutrients for health purposes.

More recent Medifast, Inc. (NYSE:MED) news were published by: Prnewswire.com which released: “Medifast, Inc. Announces 50 Percent Increase in Quarterly Dividend” on December 06, 2017. Also Prnewswire.com published the news titled: “Medifast, Inc. Announces Third Quarter 2017 Financial Results” on November 07, 2017. Prnewswire.com‘s news article titled: “Medifast, Inc. to Announce Financial Results for the Fourth Quarter and Fiscal …” with publication date: February 20, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: